The IBD SmartSelect Composite Rating for DexCom (DXCM) rose from 94 to 97 Thursday.
The new score means the company is now outperforming 97% of all stocks in terms of the most important fundamental and technical stock-picking criteria. The market’s biggest winners often have a 95 or higher score in the early stages of a new price run, so that’s an important benchmark to look for when looking for the best stocks to buy and watch.
DexCom is currently forming a consolidation, with a 125.65 buy point. With current positive action, it has cleared key moving averages. See if the stock can reach the buy point and break out in volume at least 40% above average.
Looking For The Best Stocks To Buy And Watch? Start Here
The stock earns a 97 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 97% of all stocks.
Its Accumulation/Distribution Rating of D shows moderate selling by institutional investors over the last 13 weeks. Look for the rating to improve to at least a C or better.
Earnings Update
In Q4, the company posted 0% EPS growth. Revenue growth fell to 17%, down from 18% in the previous quarter.
DexCom earns the No. 2 rank among its peers in the Medical-Products industry group. Lantheus Holdings (LNTH) is the top-ranked stock within the group.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
YOU MAY ALSO LIKE:
Join IBD Live And Learn Top Chart-Reading And Trading Techniques From The Pros
MarketSmith’s Tools Can Help The Individual Investor
Profit From Short-Term Trends With SwingTrader
Get Timely Buy & Sell Alerts With IBD Leaderboard
Find The Best Long-Term Investments With IBD Long-Term Leaders
IBD Digital: Get access to subscriber-only stock lists and market analysis. Plus, add the weekly print edition for your weekend prep.
The post DexCom Stock Gets A Composite Rating Upgrade After 4 Up Days appeared first on Investor’s Business Daily.